Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 4/20 | 0.48 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
| ▸ | RAF1 | P04049 | 1/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.38 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5764109 | 1.00 | MAPK14 (0.48) | MAPK14MAPK11EPHX2MAPK13RAF1 | |
| SCHEMBL6217964 | 0.93 | MAPK14 (0.46) | MAPK14MAPK11EPHX2MAPK13RAF1 | |
| SCHEMBL5763268 | 0.91 | MAPK11 (0.55) | MAPK14MAPK11MAPK13RAF1MAPK9 | |
| SCHEMBL6219761 | 0.91 | MAPK11 (0.44) | MAPK14MAPK11EPHX2MAPK13MAPK9 | |
| SCHEMBL5764827 | 0.89 | MAPK14 (0.50) | MAPK14MAPK11EPHX2MAPK13RAF1 | |
| SCHEMBL5763781 | 0.89 | MAPK14 (0.54) | MAPK14MAPK11MAPK13RAF1MAPK12 | |
| SCHEMBL6220074 | 0.89 | MAPK11 (0.56) | MAPK14MAPK11RAF1RPS6KB1 | |
| SCHEMBL5764069 | 0.88 | MAPK14 (0.49) | MAPK14MAPK11EPHX2MAPK13RAF1 | |
| SCHEMBL5764488 | 0.88 | MAPK14 (0.49) | MAPK14MAPK11EPHX2MAPK13RAF1 | |
| SCHEMBL5764363 | 0.88 | MAPK14 (0.49) | MAPK14MAPK11EPHX2MAPK13RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050159444-A1 | Bicyclic unsaturated tertiary amine compounds | SANKYO COMPANY, LIMITED (JP) | 2005-07-21 | — | — | US | claimed |
| EP-1541571-A1 | BICYCLIC UNSATURATED TERTIARY AMINE COMPOUND | Sankyo Company, Limited (JP) | 2005-06-15 | — | — | EP | claimed |
| US-20050159444-A1 | Bicyclic unsaturated tertiary amine compounds | SANKYO COMPANY, LIMITED (JP) | 2005-07-21 | — | — | US | disclosed |
| EP-1541571-A1 | BICYCLIC UNSATURATED TERTIARY AMINE COMPOUND | Sankyo Company, Limited (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159444-A1 | Bicyclic unsaturated tertiary amine compounds | IL1B, IL1A, STAT6 | MAPK14 340/4885MAPK11 556/4885EPHX2 1969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.